Serge Guzy

Pharmacokinetics, metabolism and safety of deuterated L‐DOPA (SD‐1077)/carbidopa compared to L‐DOPA/carbidopa following single oral dose administration in healthy subjects

Frank Schneider, Lavi Erisson, Hooman Beygi et al. · British Journal of Clinical Pharmacology · 2018 · 42 citations · Full text

Medicine, Pharmacokinetics, Pharmacology +17

A distributed delay approach for modeling delayed outcomes in pharmacokinetics and pharmacodynamics studies

Shuhua Hu, Michael R. Dunlavey, Serge Guzy et al. · Journal of Pharmacokinetics and Pharmacodynamics · 2018 · 29 citations

Pharmacy, Pharmacokinetics, Pharmacology +14

A Phase 1 Dose Escalation Study of a Fully Human, Antagonist Anti-CD40 Antibody, HCD122 (Formerly CHIR-12.12) in Patients with Relapsed and Refractory Multiple Myeloma.

William Bensinger, Sundar Jagannath, Pamela S. Becker et al. · Blood · 2006 · 23 citations

Medicine, Hematology, Immunology +16

Pharmacokinetics and Pharmacodynamics from a First-in-Human Phase 1 Dose Escalation Study with Antagonist Anti-CD40 Antibody, HCD122 (Formerly CHIR-12.12), in Patients with Relapsed and Refractory Chronic Lymphocytic Leukemia.

John C. Byrd, Ian W. Flinn, Khuda Dad Khan et al. · Blood · 2006 · 18 citations

Pharmacy, Pharmacokinetics, Pharmacology +14

Bootstrapping for Pharmacokinetic Models: Visualization of Predictive and Parameter Uncertainty

C. Anthony Hunt, Geof H. Givens, Serge Guzy · Pharmaceutical Research · 1998 · 17 citations

Pharmacy, Clinical Pharmacokinetics, Pharmacokinetics +13